A 10 mg BPC-157 vial reconstituted with 5 mL of bacteriostatic water yields a 2 mg/mL concentration identical to the standard 5 mg / 2.5 mL preparation, so the same mL values apply: 250 g = 0.125 mL, 500 g = 0.25 mL
However, the products remain absolutely identical
It upregulates the Anti-Inflammatory Gene Transcription Factor, and Human Growth Hormone receptors, all leading to better systemic repair response
It is not an FDA-approved product and has not been studied as a fixed-ratio combination in human trials
FOXO4-DRI Key Research Facts Full name: FOXO4 D-Retro-Inverso peptide (FOXO4-DRI) Classification: Cell-penetrating senolytic peptide FOXO4/p53 protein-protein interaction inhibitor Design: D-retro-inverso isoform of FOXO4s p53-binding domain reversed sequence with all D-amino acids Binding target: p53 transactivation domain 2 (TAD2) displaces FOXO4 from the FOXO4-p53 complex Mechanism: FOXO4-DRI binds p53 TAD2 p53 nuclear exclusion p53 mitochondrial translocation BAX activation caspase-3 cleavage senescent cell-selective apoptosis Selectivity basis: FOXO4 is upregulated in senescent cells but expressed at low levels in most non-senescent adult cells selectivity is mechanistically conferred D-amino acid advantage: Proteolytic stability resistant to intracellular peptidases that would rapidly degrade equivalent L-amino acid sequences Structural characterisation: NMR structural models of FOXO4-DRI/p53TAD2 complex resolved (Nature Communications, 2025) confirms disordered-to-ordered transition upon binding Research cell types studied: IMR90 fibroblasts, TM3 Leydig cells, endothelial cells, chondrocytes, keloid fibroblasts, HCT116 cancer cells In vitro working concentration: 25 M used in multiple published studies for senescent cell apoptosis induction What Does FOXO4-DRI Do in Research
An absence of intrinsic factor is the most common cause of pernicious anemia
.webp)
